Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780034 · ClinicalTrials.gov registry record · Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
A Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Accutar Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT05780034: Recruiting Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Accutar Biotechnology.
NCT05780034 is a Phase 1 study of Relapsed/Refractory B-cell Malignancies that is actively recruiting participants, run by Accutar Biotechnology. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05780034, a Phase 1 study of Relapsed/Refractory B-cell Malignancies, is actively recruiting participants, sponsored by Accutar Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Conditions Studied
Interventions
- DRUG AC676
Study Locations (9)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute - Columbus
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Oregon Health & Science University - Portland
Tennessee
- Tennessee Oncology - Nashville
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What NCT05780034 shows while recruiting
NCT05780034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Relapsed/Refractory B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AC676 is the first listed.
NCT05780034 lists 9 locations in 8 states (Ohio, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT05780034 about?
NCT05780034 is a clinical study titled "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies". This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokin...
What is the current status of trial NCT05780034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-20. Estimated completion is 2026-05-31.
What conditions does trial NCT05780034 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-cell Malignancies.
What interventions are being tested in trial NCT05780034?
The interventions under investigation include: AC676 (DRUG).
Who is sponsoring clinical trial NCT05780034?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05780034 being conducted?
This trial has 9 study locations across Colorado, Florida, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05780034's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI